Pilot study on efficacy and tolerance of peg-interferon alpha-2a (Pegasys) added to tenofovir disoproxil fumarate and emtricitabine (Truvada) in AGHBe positive HBV (hepatitis B virus)-HIV co-infected patients.

Trial Profile

Pilot study on efficacy and tolerance of peg-interferon alpha-2a (Pegasys) added to tenofovir disoproxil fumarate and emtricitabine (Truvada) in AGHBe positive HBV (hepatitis B virus)-HIV co-infected patients.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications Hepatitis B; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms HB01EMVIPEG
  • Most Recent Events

    • 14 Jan 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 21 Feb 2012 Actual patient number (56) added as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Trial phase changed from III to II/III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top